<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We studied the effect of beta 2-GPI on binding of antibodies in sera from patients with <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">leprosy</z:e> and patients with the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) to CL in enzyme-linked immunosorbent assays (ELISAs) </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0003237'>Increased levels of IgG</z:hpo> aCL were detected in 59 of 61 leprosy patients' sera by the standard aCL-ELISA in the presence of bovine beta 2-GPI and in 60 of the 61 leprosy patients' sera by the modified aCL-ELISA without beta 2-GPI </plain></SENT>
<SENT sid="2" pm="."><plain>When tested by both aCL-ELISAs on the same plate, 10/31 leprosy sera and 9/10 APS sera bound better in the standard aCL-ELISA, 16/31 leprosy sera bound better in the modified aCL-ELISA and in five <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">leprosy</z:e> and one APS sera the difference was not significant </plain></SENT>
<SENT sid="3" pm="."><plain>A dose-dependent enhancing effect of beta 2-GPI on the <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">leprosy</z:e> and APS sera binding to CL was confirmed using purified human beta 2-GPI </plain></SENT>
<SENT sid="4" pm="."><plain>Enhanced binding was seen if beta 2-GPI was added either before or together with the test serum </plain></SENT>
<SENT sid="5" pm="."><plain>In 11/61 leprosy sera <z:hpo ids='HP_0003237'>increased levels of IgG</z:hpo> antibodies against beta 2-GPI were found by ELISA </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">Leprosy</z:e> anti-beta 2-GPI antibodies appear to be a separate antibody population recognizing only beta 2-GPI adsorbed on the ELISA plate </plain></SENT>
<SENT sid="7" pm="."><plain>These results demonstrate <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> of <z:e sem="disease" ids="C0023343" disease_type="Disease or Syndrome" abbrv="">leprosy</z:e> aCL with respect to their beta 2-GPI requirement for binding to CL </plain></SENT>
</text></document>